Patterns of Medication Utilization and Costs Associated with the Use of Etanercept, Adalimumab, and Ustekinumab in the Management of Moderate-to-Severe Psoriasis

Abstract

Over one-third of psoriasis patients experienced a dose escalation of their biologic agents, and most of the dose escalation occurred during the first 6 months. Restarting, switching, and discontinuing index biologics were also common.